GSK Invests $30B in US, Shifts Away from UK
Update: 2025-12-11
Description
GSKs CEO, Dame Emma Walmsley, announces a $30 billion investment in the US pharmaceutical sector, citing frustrations with the UKs National Health Service drug budgets. Other drug makers like Merck and AstraZeneca are also shifting focus away from the UK. Dame Emma expresses optimism about a new deal with the NHS, which will increase funding for medicines and reduce tariffs on UK pharmaceutical shipments to the US. She emphasizes the importance of balancing price, access, and health outcomes, and highlights the potential of AI to accelerate innovation in health science.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
